About Element Biosciences
Element Biosciences Appoints Chief Commercial Officer, General Counsel, and VP of Operations
SAN DIEGO, Calif. — (BUSINESS WIRE) — Element Biosciences, developer of a new and disruptive DNA sequencing platform, today announced the appointments of Jeff Journey as Chief Commercial Officer, David Melaugh as General Counsel, and Jeff Labbadia as VP of Operations. “We are thrilled to welcome Jeff, David, and Jeff to the Element team,” said Molly He, Ph.D., CEO and co-founder of Element."
Element Raises $30M in Additional Series B Financing to Accelerate Development of a New Sequencing Platform
SAN DIEGO, Calif. — Element Biosciences closed an additional $30M in Series B financing, with participation from new investors RA Capital Management and Alexandria Venture Investments. To date, the company has raised a total of more than $130 million. Proceeds from the financing will be used to accelerate the development of high-quality, low-cost, and easy-to-use genomic sequencing solutions.
Element Raises $80M in Series B Financing to Accelerate Development of a New Sequencing Platform
SAN DIEGO, Calif. — Element Biosciences today announced the close of a Series B financing round of $80.3 million, with participation from new investors Fidelity Management & Research Company and JS Capital LLC, as well as existing investors Foresite Capital and Venrock. To date, the company has raised a total of more than $100 million. Proceeds from the financing will be used to accelerate the...
Element Biosciences Moves to Alexandria GradLabs in Anticipation of Growth and Expansion
December 16, 2019
SAN DIEGO, Calif. — Element Biosciences took an exciting step toward our future growth. We recently moved our headquarters in San Diego to Alexandria GradLabs in University Town Center! GradLabs is an amazing new idea from a fellow innovator, Alexandria Real Estate Equities, Inc. – it provides early-stage life science companies with turnkey, fully furnished office/lab suites designed to engage talents...
Element Biosciences Secures $15 Million Series A Financing Led by Foresite Capital and Venrock
SAN DIEGO, Calif. — Element Biosciences, Inc., a company focused on the development of genetic analysis tools secures $15 million in Series A funding led by Foresite Capital and Venrock. Proceeds from the financing will support the development of disruptive technologies designed to significantly improve quality and reduce the cost of genomic applications...